BioCentury | Nov 5, 2019
Product Development

Senti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In silico , cell culture and mouse studies identified a PGA3-derived antimicrobial peptide that could help treat bacterial infection. In silico screening of amino acid sequences of human secreted proteins for structural similarity...
BioCentury | Feb 27, 2018
Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
BioCentury | Apr 21, 2014
Company News

Anika, J&J sales and marketing update

Anika said its U.S. commercialization partner, the DePuy Synthes Mitek Sports Medicine division of Johnson & Johnson's DePuy Orthopedics Inc. subsidiary, launched Monovisc for osteoarthritis (OA) in the U.S. The launch triggered a $5 million...
BioCentury | Jan 27, 2014
Financial News

Synthelis completes venture financing

Synthelis , La Tronche, France Business: Proteomics, Supply/Service Date completed: 1/21/14 Type: Venture financing Raised: €610,000 ($826,916) Investors: Rhone Alpes Creation; Alpes Developpement Durable Investissement; Sud Rhone-Alpes Capital; Viaduc; angel investors WIR Staff...
BioCentury | Jun 3, 2013
Company News

Campus Biotech S.A., Merck KGaA, Ecole Polytechnique Federale de Lausanne (EPFL), University of Geneva (UNIGE) other, pharmaceuticals news

Campus Biotech said the sale of the former headquarters of Merck's Merck Serono S.A. biotech division in Geneva to the consortium behind the Campus Biotech initiative has been finalized. Hansjorg Wyss, the founder of Synthes...
BioCentury | Dec 17, 2012
Company News

Alere management update

Alere Inc. (NYSE:ALR), Waltham, Mass. Business: Diagnostic Hired: Namal Nawana as COO, effective Dec. 30, formerly president of Johnson Johnson's DePuy Synthes Spine Inc. subsidiary WIR Staff Diagnostic...
BioCentury | Dec 10, 2012
Company News

Campus Biotech S.A., Merck KGaA other news

A pair of billionaires made an undisclosed bid to purchase the former headquarters of Merck's Merck Serono biotech division in Geneva. Hansjorg Wyss, the founder of Synthes Inc., and Ernesto Bertarelli, the former CEO of...
BioCentury | Dec 8, 2012
Company News

Billionaires make bid for former Merck Serono headquarters

A pair of billionaires made an undisclosed bid to purchase the former headquarters of the Merck Serono biotech division of Merck KGaA (Xetra:MRK) in Geneva, Switzerland. Hansjorg Wyss, the founder of Synthes Inc., and Ernesto...
BioCentury | Sep 3, 2012
Company News

Axial Biotech, Transgenomic deal

Transgenomic will acquire assets and IP related to Axial's ScoliScore Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for about $4.4 million in cash. The PCR-based genetic test is approved in the U.S. to determine the risk...
Items per page:
1 - 10 of 20
BioCentury | Nov 5, 2019
Product Development

Senti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In silico , cell culture and mouse studies identified a PGA3-derived antimicrobial peptide that could help treat bacterial infection. In silico screening of amino acid sequences of human secreted proteins for structural similarity...
BioCentury | Feb 27, 2018
Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
BioCentury | Apr 21, 2014
Company News

Anika, J&J sales and marketing update

Anika said its U.S. commercialization partner, the DePuy Synthes Mitek Sports Medicine division of Johnson & Johnson's DePuy Orthopedics Inc. subsidiary, launched Monovisc for osteoarthritis (OA) in the U.S. The launch triggered a $5 million...
BioCentury | Jan 27, 2014
Financial News

Synthelis completes venture financing

Synthelis , La Tronche, France Business: Proteomics, Supply/Service Date completed: 1/21/14 Type: Venture financing Raised: €610,000 ($826,916) Investors: Rhone Alpes Creation; Alpes Developpement Durable Investissement; Sud Rhone-Alpes Capital; Viaduc; angel investors WIR Staff...
BioCentury | Jun 3, 2013
Company News

Campus Biotech S.A., Merck KGaA, Ecole Polytechnique Federale de Lausanne (EPFL), University of Geneva (UNIGE) other, pharmaceuticals news

Campus Biotech said the sale of the former headquarters of Merck's Merck Serono S.A. biotech division in Geneva to the consortium behind the Campus Biotech initiative has been finalized. Hansjorg Wyss, the founder of Synthes...
BioCentury | Dec 17, 2012
Company News

Alere management update

Alere Inc. (NYSE:ALR), Waltham, Mass. Business: Diagnostic Hired: Namal Nawana as COO, effective Dec. 30, formerly president of Johnson Johnson's DePuy Synthes Spine Inc. subsidiary WIR Staff Diagnostic...
BioCentury | Dec 10, 2012
Company News

Campus Biotech S.A., Merck KGaA other news

A pair of billionaires made an undisclosed bid to purchase the former headquarters of Merck's Merck Serono biotech division in Geneva. Hansjorg Wyss, the founder of Synthes Inc., and Ernesto Bertarelli, the former CEO of...
BioCentury | Dec 8, 2012
Company News

Billionaires make bid for former Merck Serono headquarters

A pair of billionaires made an undisclosed bid to purchase the former headquarters of the Merck Serono biotech division of Merck KGaA (Xetra:MRK) in Geneva, Switzerland. Hansjorg Wyss, the founder of Synthes Inc., and Ernesto...
BioCentury | Sep 3, 2012
Company News

Axial Biotech, Transgenomic deal

Transgenomic will acquire assets and IP related to Axial's ScoliScore Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for about $4.4 million in cash. The PCR-based genetic test is approved in the U.S. to determine the risk...
Items per page:
1 - 10 of 20